Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Hypersensitivity Reaction

Free Subscription Articles published in Eur J Dermatol Retrieve available abstracts of 36 articles: HTML format

Single Articles

April 2026
1. TAKAHASHI Y, Hagino T, Uchiyama A, Saeki H, et al
   Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and >/= 65 years).
   Eur J Dermatol. 2026;36:156-165.
   PubMed     Abstract available
   
   
   February 2026
2. KIM J, Pak K, Lee J, Shin K, et al
   Improvement of depressive symptoms in patients with severe atopic dermatitis treated with dupilumab: an open-label trial validated using the Beck depression inventory, Hamilton depression rating scale measures, and 18F-fluorodeoxyglucose positron emis
   Eur J Dermatol. 2026;36:73-75.
   PubMed    
   
   
   
3. UGAJIN T, Yamamoto-Murata M
   Onset of furosemide-triggered bullous pemphigoid, possibly induced by CD8-positive T cell-mediated hypersensitivity reactions to drug and ultraviolet exposure.
   Eur J Dermatol. 2026;36:68-70.
   PubMed    
   
   
   December 2025
4. KOMATSU-FUJII T, Cho R, Nomiyama T, Yamamoto Y, et al
   Clinical outcome of alopecia areata in patients with atopic dermatitis treated with dupilumab combined with topical immunotherapy: a case series.
   Eur J Dermatol. 2025;35:519-526.
   PubMed     Abstract available
   
   
   October 2025
5. TOYOSHIMA M, Nakaoji K, Hamada K, Yamanaka A, et al
   Analysis of skin aging patterns using a facial imaging system in atopic dermatitis patients of 20-34 years old.
   Eur J Dermatol. 2025;35:424-426.
   PubMed    
   
   
   June 2025
6. UCHIYAMA A, Ishikawa M, Kosaka K, Motegi SI, et al
   Effectiveness and safety of dupilumab in Japanese paediatric patients with atopic dermatitis: a multiple-centre retrospective study in a real-life setting in Gunma Prefecture.
   Eur J Dermatol. 2025;35:250-252.
   PubMed    
   
   
   
7. MINAKAWA F, Yanagida N, Sugiyama S, Toi Y, et al
   Differences in the management of toxic epidermal necrolysis related and unrelated to immune checkpoint inhibitors.
   Eur J Dermatol. 2025;35:224-229.
   PubMed     Abstract available
   
   
   April 2025
8. KATO M, Igawa K, Ando Y, Miyamoto M, et al
   A paediatric case of severe atopic dermatitis with prurigo nodularis successfully treated with nemolizumab as second-line therapy.
   Eur J Dermatol. 2025;35:131-132.
   PubMed    
   
   
   
9. ANDELIC M, Groen SS, Holm JG, Egeberg A, et al
   A novel biomarker of type VII collagen degradation increases in patients with atopic dermatitis and decreases upon treatment with immunosuppressants.
   Eur J Dermatol. 2025;35:91-97.
   PubMed     Abstract available
   
   
   February 2025
10. BERNARDO D, Alvarenga JM, Torres T
    Effectiveness and safety of dupilumab in adults with moderate-to-severe atopic dermatitis previously treated with JAK inhibitors.
    Eur J Dermatol. 2025;35:64-65.
    PubMed    
    
    
    
11. CHO E, Kim J, Kang B, Liu K, et al
    Skin condition and barrier function in individuals with a history of atopic dermatitis.
    Eur J Dermatol. 2025;35:16-24.
    PubMed     Abstract available
    
    
    December 2024
12. SUZUKI Y, Fujiwara M, Takeshita H, Namiki T, et al
    Avoidable anaphylactic shock due to chlorhexidine gluconate in the oral cavity.
    Eur J Dermatol. 2024;34:681-682.
    PubMed    
    
    
    
13. DEZOTEUX F, Staumont-Salle D
    DRESS (drug reaction with eosinophilia and systemic symptoms): a possible prolonged course with sequelae.
    Eur J Dermatol. 2024;34:587-594.
    PubMed     Abstract available
    
    
    October 2024
14. REYNAUD V, Dege T, Byrne N, Garcia-Piqueras P, et al
    Journal club: Biomarkers for atopic dermatitis: current use and perspectives.
    Eur J Dermatol. 2024;34:567-569.
    PubMed    
    
    
    
15. FREITAS E, Yilmaz O, Torres T
    Effectiveness and tolerance of tralokinumab after failure with dupilumab and baricitinib in a patient with atopic dermatitis.
    Eur J Dermatol. 2024;34:551-553.
    PubMed    
    
    
    
16. IKEZAWA S, Yokoyama E, Urakami H, Takigawa M, et al
    A case of anaphylaxis to kumquat (Citrus japonica).
    Eur J Dermatol. 2024;34:539-541.
    PubMed    
    
    
    
17. HAGINO T, Onda M, Saeki H, Fujimoto E, et al
    Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan.
    Eur J Dermatol. 2024;34:525-532.
    PubMed     Abstract available
    
    
    
18. METSINI A, Ryen L, Montgomery S, Svensson A, et al
    Healthcare visits, patterns of treatment, and related costs in children with controlled and uncontrolled atopic dermatitis in Sweden.
    Eur J Dermatol. 2024;34:509-516.
    PubMed     Abstract available
    
    
    August 2024
19. NEUBAUER C, Kragl M, Braun T, Filipek P, et al
    An oil-in-water emulsion containing a combination of ginger extract and synthetic cannabidiol with potent in vitro anti-inflammatory effects alleviates symptoms of atopic dermatitis in a clinical trial.
    Eur J Dermatol. 2024;34:416-424.
    PubMed     Abstract available
    
    
    
20. URENA-PANIEGO C, Sanabria-De-La-Torre R, Ramirez-Munoz A, Soto-Moreno A, et al
    Response to biological drugs and JAK inhibitors following cyclosporine in patients with atopic dermatitis.
    Eur J Dermatol. 2024;34:409-415.
    PubMed     Abstract available
    
    
    
21. SOKOLOVSKIS A, Lapina L, Lauva A, Papirte S, et al
    Epidemiological and clinical characteristics of adult patients with chronic spontaneous urticaria in Latvia: insights from a two-centre study.
    Eur J Dermatol. 2024;34:398-408.
    PubMed     Abstract available
    
    
    
22. GAMBICHLER T, Ardabili L, Domin B, Susok L, et al
    Predictors of disease severity, length of hospitalization, and recurrence in inpatients with single-organ cutaneous small vessel vasculitis.
    Eur J Dermatol. 2024;34:378-383.
    PubMed     Abstract available
    
    
    
23. ZHOU X, Su J, Zhang CL, Dai H, et al
    Decreased expression of galectin-3 in the epidermis of psoriasis patients.
    Eur J Dermatol. 2024;34:371-377.
    PubMed     Abstract available
    
    
    
24. BAKAR J, Michael-Jubeli R, Salmon M, Lancelot C, et al
    Effect of Th2 cytokines on ceramide subclasses based on a model of reconstructed human epidermis.
    Eur J Dermatol. 2024;34:361-370.
    PubMed     Abstract available
    
    
    June 2024
25. GAMBICHLER T, Sandersfeld MH, Schaller J, Wiech T, et al
    Adult Henoch-Schonlein purpura complicated by IgA-nephritis in a patient with mantle cell lymphoma and Graves disease.
    Eur J Dermatol. 2024;34:318-320.
    PubMed    
    
    
    
26. FOTI C, Calianno G, Sbarra G, Pisani MC, et al
    Crusted scabies diagnosed in an atopic patient during treatment with upadacitinib.
    Eur J Dermatol. 2024;34:311-312.
    PubMed    
    
    
    
27. YOSHIDA S, Shiraishi K, Yatsuzuka K, Kohri N, et al
    Effects of hot bath therapy on cholinergic urticaria with hypohidrosis or anhidrosis.
    Eur J Dermatol. 2024;34:271-275.
    PubMed     Abstract available
    
    
    February 2024
28. FUKUDA H, Aoki S, Harada Y, Matsumoto C, et al
    A case of acute generalized exanthematous pustulosis caused by eperisone hydrochloride.
    Eur J Dermatol. 2024;34:97-98.
    PubMed    
    
    
    
29. OUNI B, Mansour K, Sassi M, Sriha B, et al
    Silodosin-induced leukocytoclastic vasculitis: a first case report.
    Eur J Dermatol. 2024;34:92-93.
    PubMed    
    
    
    
30. GIMENEZ-ARNAU AM, Salman A, Podder I
    Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
    Eur J Dermatol. 2024;34:3-12.
    PubMed     Abstract available
    
    
    December 2023
31. DE GREEF A, Ghislain PD, Baeck M
    Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2023;33:707-709.
    PubMed    
    
    
    
32. NISHIYORI R, Sakai T, Nishida H, Hatano Y, et al
    An unusual case of immediate and delayed hypersensitivity to wasp stings.
    Eur J Dermatol. 2023;33:701-703.
    PubMed    
    
    
    
33. TSAI YC, Tsai TF
    Successful treatment of atopic dermatitis by switching from upadacitinib to abrocitinib: a case report.
    Eur J Dermatol. 2023;33:699-701.
    PubMed    
    
    
    
34. MIYAWAKI K, Nakashima C, Otsuka A
    Real-world effectiveness and safety of nemolizumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
    Eur J Dermatol. 2023;33:691-692.
    PubMed    
    
    
    
35. LAMOLET M, Barbarin C, Renaud O, Sahin Y, et al
    Acceleration of cutaneous T-cell lymphoma mistaken for atopic dermatitis following JAK inhibitor use.
    Eur J Dermatol. 2023;33:686-687.
    PubMed    
    
    
    
36. COHEN E, Lheure C, Ingen-Housz-Oro S, Hotz C, et al
    Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients.
    Eur J Dermatol. 2023;33:680-685.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum